Antibody-maytansinoid conjugates designed to bypass multidrug resistance

Cancer Research

Volumn 70, Issue 6, 2010, Pages 2528-2537

  Kovtun, Yelena V ^a   Audette, Charlene A ^a   Mayo, Michele F ^a   Jones, Gregory E ^a   Doherty, Heather ^a   Maloney, Erin K ^a   Erickson, Hans K ^a   Sun, Xiuxia ^a   Wilhelm, Sharon ^a   Ab, Olga ^a   Lai, Katharine C ^a   Widdison, Wayne C ^a   Kellogg, Brenda ^a   Johnson, Holly ^a   Pinkas, Jan ^a   Lutz, Robert J ^a   Singh, Rajeeva ^a   Goldmacher, Victor S ^a   Chari, Ravi V J ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CANAG ANTIBODY C242 CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY CONJUGATE; EPITHELIAL CELL ADHESION MOLECULE MONOCLONAL ANTIBODY B38.1 CONJUGATE; ETHYLENE GLYCOL; MALEIMIDE DERIVATIVE; MAYTANSINE; MULTIDRUG RESISTANCE PROTEIN 1; N SUCCINIMIDYL 4 (MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBOXYLATE; PACLITAXEL; SUCCINIMIDE DERIVATIVE; TETRAMER; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HYDROPHILICITY; METABOLITE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TARGET CELL; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA, RENAL CELL; CELL ADHESION MOLECULES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOTOXINS; KIDNEY NEOPLASMS; MALEIMIDES; MAYTANSINE; MICE; MICE, SCID; P-GLYCOPROTEIN; POLYETHYLENE GLYCOLS;

EID: 77950224905     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3546     Document Type: Article

References (39)

1. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-234
2. Wilson TR, Longley DB, Johnston PG. Chemoresistance in solid tumours. Ann Oncol 2006;17 Suppl 10:x315-24.
3. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9:105-127
4. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 2006;12:273-286
5. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-424
6. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14:154-169
7. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 2005;5:543-549
8. Matsui H, Takeshita A, Naito K, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 2002;16:813-819
9. Walter RB, Gooley TA, van der Velden VH, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007;109:4168-4170
10. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003;102:1466-1473
11. Tang R, Cohen S, Perrot JY, et al. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer 2009;9:199.
12. Toppmeyer DL, Slapak CA, Croop J, Kufe DW. Role of P-glycoprotein in dolastatin 10 resistance. Biochem Pharmacol 1994;48:609-612
13. Butryn RK, Smith KS, Adams EG, et al. V79 Chinese hamster lung cells resistant to the bis-alkylator bizelesin are multidrug-resistant. Cancer Chemother Pharmacol 1994;34:44-50.
14. Zsido TJ, Beerman TA, Meegan RL, Woynarowski JM, Baker RM. Resistance of CHO cells expressing P-glycoprotein to cyclopropylpyrroloindole (CPI) alkylating agents. Biochem Pharmacol 1992;43: 1817-1822.
15. Takeshita A, Shinjo K, Yamakage N, et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol 2009;146:34-43.
16. Hamann PR, Hinman LM, Beyer CF, et al. An anti-MUC1 antibody- calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Bioconjug Chem 2005;16:346-353
17. Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets 2000;1:85-99.
18. Guillemard V, Uri Saragovi H. Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene 2004;23:3613-3621
19. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-4433
20. Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114-124
21. Goldmacher VS, Blättler WA, Lambert JM, Chari RVJ. Immunotoxins and antibody-drug conjugates for cancer treatment. In: Muzykantov V, Torchilin V, editors. Biomedical aspects of drug targeting. Boston/ Dordrecht/London: Kluwer Academic Publishers; 2002, p. 291-309.
22. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983; 221:1285-1288
23. Widdison WC, Wilhelm SD, Cavanagh EE, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392-4408
24. Loo TW, Clarke DM. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 2005; 206:173-185
25. Liu C, Tadayoni BM, Bourret LA, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci U S A 1996;93:8618-8623
26. Roguska MA, Pedersen JT, Keddy CA, et al. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci U S A 1994;91:969-973
27. Chari RV, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992; 52:127-131
28. Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-3221
29. Pallis M, Das-Gupta E. Flow cytometric measurement of functional and phenotypic P-glycoprotein. Methods Mol Med 2005;111: 167-181
30. Smith CD, Myers CB, Zilfou JT, Smith SN, Lawrence DS. Indoloquinoxaline compounds that selectively antagonize P-glycoprotein. Oncol Res 2000;12:219-229
31. Gekeler V, Ise W, Sanders KH, Ulrich WR, Beck J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 1995; 208:345-352
32. Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1:611-616
33. Minderman H, Suvannasankha A, O'Loughlin KL, et al. Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 2002;48:59-65.
34. Hugger ED, Novak BL, Burton PS, Audus KL, Borchardt RT. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 2002;91:1991-2002.
35. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-9290
36. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98-107.
37. Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993;268:21493-21496
38. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, Gottesman MM. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 1990;265: 3975-3980
39. Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323: 1718-1722